NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $52.44 -2.39 (-4.36%) (As of 08:41 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Soleno Therapeutics Stock (NASDAQ:SLNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$52.44▼$52.4450-Day Range$46.88▼$59.1852-Week Range$26.38▼$59.75Volume465 shsAverage Volume467,002 shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$74.83Consensus RatingBuy Company OverviewSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Soleno Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks80th Percentile Overall ScoreSLNO MarketRank™: Soleno Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 224th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soleno Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -16.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 8.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.09% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.55 Percentage of Shares Shorted20.09% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Soleno Therapeutics this week, compared to 3 articles on an average week.Search Interest11 people have searched for SLNO on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,970,517.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLNO Stock News HeadlinesSoleno Therapeutics Reports Q3 Progress and FinancialsNovember 21 at 5:38 AM | markets.businessinsider.comSoleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024November 14, 2024 | globenewswire.comBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.November 21, 2024 | Brownstone Research (Ad)Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn SituationNovember 12, 2024 | finance.yahoo.comPositive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash PositionNovember 9, 2024 | markets.businessinsider.comCantor Fitzgerald Remains a Buy on Soleno Therapeutics (SLNO)November 8, 2024 | markets.businessinsider.comSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | finance.yahoo.comSoleno Therapeutics (NASDAQ:SLNO) Stock, Option ChainNovember 3, 2024 | benzinga.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $40.25 at the start of the year. Since then, SLNO stock has increased by 36.2% and is now trading at $54.83. View the best growth stocks for 2024 here. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its earnings results on Wednesday, November, 6th. The company reported ($1.83) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $1.22. When did Soleno Therapeutics' stock split? Soleno Therapeutics's stock reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Soleno Therapeutics' major shareholders? Soleno Therapeutics' top institutional shareholders include Janus Henderson Group PLC (9.46%), State Street Corp (2.65%), Vestal Point Capital LP (1.67%) and Wellington Management Group LLP (1.58%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Bhatnagar Anish, Jack W Schuler, James H Mackaness and Kristen Yen. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), Disc Medicine (IRON), Arista Networks (ANET) and Adobe (ADBE). Company Calendar Last Earnings11/06/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$74.83 High Stock Price Target$93.00 Low Stock Price Target$67.00 Potential Upside/Downside+36.5%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.99% Return on Assets-55.21% Debt Debt-to-Equity RatioN/A Current Ratio17.26 Quick Ratio17.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book10.63Miscellaneous Outstanding Shares43,120,000Free Float37,814,000Market Cap$2.36 billion OptionableOptionable Beta-1.44 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:SLNO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.